<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266837</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001LDE36T</org_study_id>
    <secondary_id>2010-021370-11</secondary_id>
    <nct_id>NCT01266837</nct_id>
  </id_info>
  <brief_title>Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)</brief_title>
  <acronym>MARC-2</acronym>
  <official_title>An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic&#xD;
      renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients progression free 6 months after start of study treatment</measure>
    <time_frame>2 years after LPI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relation between biomarkers and clinical benefit (response, stable disease and progression/ no clinical benefit) of patients</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <condition>Failure of Exactly One Prior VEGF-targeted Therapy</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with Everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg p.o once daily</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent&#xD;
&#xD;
          2. Aged 18 years and above&#xD;
&#xD;
          3. Histologically or cytologically confirmed predominantly clear cell renal cell&#xD;
             carcinoma&#xD;
&#xD;
          4. Metastatic disease documented by CT or MRI (histological confirmation not mandatory&#xD;
             but wishful)&#xD;
&#xD;
          5. Patients with or without nephrectomy (partial or total)&#xD;
&#xD;
          6. Patients with at least one measurable lesion at baseline according to RECIST criteria&#xD;
             1.1&#xD;
&#xD;
          7. Failure of exactly one prior VEGFR-TKI therapy (e.g. sunitinib, sorafenib, pazopanib)&#xD;
             for metastatic renal cell carcinoma&#xD;
&#xD;
          8. ECOG 0-2&#xD;
&#xD;
          9. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
         10. Platelet count ≥75,000/μL&#xD;
&#xD;
         11. Absolute neutrophil count ≥1,5x109/l&#xD;
&#xD;
         12. Serum creatinine &lt; 2.5 x ULN&#xD;
&#xD;
         13. Liver function: Serum bilirubin ≤ 1.5 x ULN, AST or ALT ≤ 2.5 x ULN. Patients with&#xD;
             suspected liver metastasis: AST and ALT ≤ 5x ULN&#xD;
&#xD;
         14. Able to swallow the study drug whole as a tablet&#xD;
&#xD;
         15. Expected life expectancy of at least 6 months&#xD;
&#xD;
         16. Women of childbearing potential must have had a negative serum pregnancy test within&#xD;
             14 days prior to the administration of the study treatment or must have a documented&#xD;
             condition that prohibits pregnancy (e.g. hysterectomy, post-menopausal).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received &gt;1 prior VEGFR-TKI therapy or prior therapy with&#xD;
             bevacizumab +/- interferon.&#xD;
&#xD;
          2. VEGFR-TKI therapy within 14 days prior to start of study drug&#xD;
&#xD;
          3. Patients who have previously received systemic mTOR inhibitors (sirolimus,&#xD;
             temsirolimus, everolimus).&#xD;
&#xD;
          4. Patients with a known hypersensitivity to everolimus or other rapamycin (sirolimus,&#xD;
             temsirolimus) or to its excipients.&#xD;
&#xD;
          5. Any condition which, in the opinion of the investigator, would preclude participation&#xD;
             in this trial&#xD;
&#xD;
          6. Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or&#xD;
             intrapelvic), open biopsy, or significant traumatic injury to avoid wound healing&#xD;
             complications. Minor procedures and percutaneous biopsies or placement of vascular&#xD;
             access device require 7 days prior to study entry.&#xD;
&#xD;
          7. Patients who had radiation therapy within 4 weeks prior to start of study treatment.&#xD;
             Palliative radiotherapy to bone lesions within 2 weeks prior to study treatment start.&#xD;
&#xD;
          8. Patients in anticipation of the need for major surgical procedure during the course of&#xD;
             the study.&#xD;
&#xD;
          9. Patients with a serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         10. Patients with a history of seizure(s) not controlled with standard medical therapy.&#xD;
&#xD;
         11. History or clinical evidence of central nervous system (CNS) metastases. Subjects who&#xD;
             have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma&#xD;
             knife) and meet all 3 of the following criteria are eligible:&#xD;
&#xD;
               1. are asymptomatic and,&#xD;
&#xD;
               2. have had no evidence of active CNS metastases for ≥ 3 months prior to enrolment&#xD;
                  (inactive/controlled CNS metastases are allowed) and,&#xD;
&#xD;
               3. have no requirement for steroids or enzyme-inducing anticonvulsants (e.g.&#xD;
                  carbamazepine, phenobarbital, phenytoin)&#xD;
&#xD;
         12. Patients receiving chronic systemic treatment with corticosteroids (dose of &gt; 10&#xD;
             mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and&#xD;
             topical steroids are acceptable.&#xD;
&#xD;
         13. Poorly controlled diabetes as defined by fasting serum glucose &gt;2.0 x ULN.&#xD;
&#xD;
         14. Impaired liver function classified as Child-Pugh class C.&#xD;
&#xD;
         15. Active (acute or chronic) or uncontrolled infection of bacterial, mycotic or viral&#xD;
             genesis.&#xD;
&#xD;
         16. Liver disease such as chronic active hepatitis or chronic persistent hepatitis.&#xD;
&#xD;
         17. Patients with a known history of HIV seropositivity.&#xD;
&#xD;
         18. Patients with active bleeding disorders.&#xD;
&#xD;
         19. Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions within the past 12 months that could affect their participation in the&#xD;
             study such as cardiac angioplasty or stenting, unstable angina pectoris, symptomatic&#xD;
             peripheral vascular disease, symptomatic congestive heart failure (NYHA II, III, IV),&#xD;
             myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled&#xD;
             cardiac arrhythmia, any disorders that impair the ability to evaluate the patient or&#xD;
             for the patient to complete the study.&#xD;
&#xD;
         20. Patients who have a history of another primary malignancy and off treatment for ≤ 3&#xD;
             years, with the exception of non-melanoma skin cancer and carcinoma in situ of the&#xD;
             uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 -&#xD;
             T2).&#xD;
&#xD;
         21. Female patients who are pregnant or breast feeding.&#xD;
&#xD;
         22. Men and women of reproductive potential who are not using highly effective birth&#xD;
             control methods. Oral contraceptives for female patients and barrier contraceptives&#xD;
             are not acceptable. For definition of highly effective birth control methods please&#xD;
             refer to section 12.3.6 of this protocol.&#xD;
&#xD;
         23. Patients who are using other investigational agents or who had received&#xD;
             investigational drugs ≤ 2 weeks prior to study treatment start.&#xD;
&#xD;
         24. Patients unwilling or unable to comply with the protocol.&#xD;
&#xD;
         25. Exclusion criteria for MRI: intracorporal metal (e.g. incompatible heart valves,&#xD;
             pacemakers), contrast media allergy, claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Staehler, Dr. med</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilians-University Munich, Hospital Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charitè Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Urologie , Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie - Waldkrankenhaus St. Marien</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin (Tumorforschung), Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum Innere Medizin, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Urologie, Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5. Medizinische Klinik, Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic renal cell carcinoma</keyword>
  <keyword>biomarker</keyword>
  <keyword>Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

